Deutsch names Dowshen to head Zelnorm and Diovan business

Share this article:
Deutsch named Matt Dowshen to head the firm's business on Novartis' Zelnorm and Diovan. Dowshen, who joined from JWT New York, where he was senior partner/director-in-charge and co-leader of the DeBeers account, becomes SVP/group account director at Deutsch New York. In addition to the Novartis business, he will head the firm's IKEA account, reporting to Deutsch New York president Val DiFebo.
Share this article:
close

Next Article in News

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.